Literature DB >> 21641911

Detection of proliferative responses to ESAT-6 and CFP-10 by FASCIA assay for diagnosis of Mycobacterium tuberculosis infection.

Emilie Borgström1, Peter Andersen, Lena Andersson, Inger Julander, Gunilla Källenius, Markus Maeurer, Maria Norrby, Ida Rosenkrands, Teghesti Tecleab, Judith Bruchfeld, Hans Gaines.   

Abstract

There is a large and growing worldwide need for reliable tests to diagnose active and latent tuberculosis (TB). Improved methodology for identifying individuals with true latent TB (LTBI), particularly those with a recent infection, would pave the way for targeted prophylactic treatment. The traditionally used tuberculin skin test (TST) is unspecific and impractical. Interferon gamma release assays (IGRA) are more specific than the TST but, like that test, cannot discriminate either between recent and remote TB infection, or between these and a mere immunological memory of previous TB infection. The Flow-cytometric Assay for Specific Cell-mediated Immune-response in Activated whole blood (FASCIA) combines long-term antigen stimulation of whole blood and flow-cytometric analysis with quantification of the expanded T-lymphoblasts and can also be employed for measurement of cytokine responses.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21641911     DOI: 10.1016/j.jim.2011.05.008

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  7 in total

1.  Effect of isoniazid therapy for latent TB infection on QuantiFERON-TB gold in-tube responses in adults with positive tuberculin skin test results in a high TB incidence area: a controlled study.

Authors:  John L Johnson; Hendrik Geldenhuys; Bonnie A Thiel; Asma Toefy; Sara Suliman; Bernadette Pienaar; Phalkun Chheng; Thomas Scriba; W Henry Boom; Willem Hanekom; Mark Hatherill
Journal:  Chest       Date:  2014-03-01       Impact factor: 9.410

2.  Immune responses to ESAT-6 and CFP-10 by FASCIA and multiplex technology for diagnosis of M. tuberculosis infection; IP-10 is a promising marker.

Authors:  Emilie Borgström; Peter Andersen; Fredrik Atterfelt; Inger Julander; Gunilla Källenius; Markus Maeurer; Ida Rosenkrands; Maria Widfeldt; Judith Bruchfeld; Hans Gaines
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

3.  Leukocyte proliferation and immune modulator production in patients with chronic kidney disease.

Authors:  Ladan Mansouri; Josefin M Paulsson; Ali Moshfegh; Stefan H Jacobson; Joachim Lundahl
Journal:  PLoS One       Date:  2013-08-09       Impact factor: 3.240

4.  Identification of Mycobacterium tuberculosis Infection in Infants and Children With Partial Discrimination Between Active Disease and Asymptomatic Infection.

Authors:  Alexandra Dreesman; Violette Dirix; Kaat Smits; Véronique Corbière; Anne Van Praet; Sara Debulpaep; Iris De Schutter; Mariet-Karlijn Felderhof; Anne Malfroot; Mahavir Singh; Camille Locht; Françoise Mouchet; Françoise Mascart
Journal:  Front Pediatr       Date:  2019-07-25       Impact factor: 3.418

5.  Comparison of the change in QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube results after preventive therapy for latent tuberculosis infection.

Authors:  Ock-Hwa Kim; Kyung-Wook Jo; Shinhee Park; Yong-Ha Jo; Mi-Na Kim; Heungsup Sung; Tae Sun Shim
Journal:  PLoS One       Date:  2020-06-16       Impact factor: 3.240

6.  Specific T-cell responses for guiding treatment with convalescent plasma in severe COVID-19 and humoral immunodeficiency: a case report.

Authors:  Katarina Nyström; Maria Hjorth; Ramona Fust; Åsa Nilsdotter-Augustinsson; Marie Larsson; Katarina Niward; Sofia Nyström
Journal:  BMC Infect Dis       Date:  2022-04-11       Impact factor: 3.090

7.  Differential cellular recognition pattern to M. tuberculosis targets defined by IFN-γ and IL-17 production in blood from TB + patients from Honduras as compared to health care workers: TB and immune responses in patients from Honduras.

Authors:  Nancy Alvarez-Corrales; Raija K Ahmed; Carol A Rodriguez; Kithiganahalli N Balaji; Rebeca Rivera; Ramakrishna Sompallae; Nalini K Vudattu; Sven E Hoffner; Alimuddin Zumla; Lelany Pineda-Garcia; Markus Maeurer
Journal:  BMC Infect Dis       Date:  2013-03-06       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.